Related references
Note: Only part of the references are listed.Prediction of Fluoroquinolone-Induced Elevation in Serum Creatinine Levels: A Case of Drug-Endogenous Substance Interaction Involving the Inhibition of Renal Secretion
Y. Imamura et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
New Clues for Nephrotoxicity Induced by Ifosfamide: Preferential Renal Uptake via the Human Organic Cation Transporter 2
Giuliano Ciarimboli et al.
MOLECULAR PHARMACEUTICS (2011)
SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients
Kayo Osawa
PHARMACOGENOMICS (2011)
Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions
Giuliano Ciarimboli et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Relation Between Renal Dysfunction Requiring Renal Replacement Therapy and Promoter Polymorphism of the Erythropoietin Gene in Cardiac Surgery
Aron F. Popov et al.
ARTIFICIAL ORGANS (2010)
Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase
Ryan M. Franke et al.
CLINICAL CANCER RESEARCH (2010)
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial
Adam Vilmar et al.
EUROPEAN JOURNAL OF CANCER (2010)
New loci associated with kidney function and chronic kidney disease
Anna Koettgen et al.
NATURE GENETICS (2010)
Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies
Mladen Vassilev Tzvetkov et al.
PHARMACOGENOMICS (2010)
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients
A. V. Khrunin et al.
PHARMACOGENOMICS JOURNAL (2010)
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
K. K. Filipski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin
M. V. Tzvetkov et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Chemotherapy-associated renal dysfunction
Vaibhav Sahni et al.
NATURE REVIEWS NEPHROLOGY (2009)
Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2)
Oliver Zolk et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes
Penelope A. Bradbury et al.
PHARMACOGENETICS AND GENOMICS (2009)
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD
Lesley A. Stevens et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
L. Pare et al.
BRITISH JOURNAL OF CANCER (2008)
A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients
Andreas Woelfelschneider et al.
CARCINOGENESIS (2008)
Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer:: GSTM1-present genotype is associated with better prognosis in completely resected patients
Katja Ott et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2008)
Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer
Thomas C. Krivak et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
N. Pabla et al.
KIDNEY INTERNATIONAL (2008)
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis
Sunita J. Shukla et al.
PHARMACOGENETICS AND GENOMICS (2008)
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications
Zongzhong Tong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer
Zhao-Hui Huang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and-M1, a retrospective cross sectional study
Jan Oldenburg et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer
Sharon Marsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk:: a meta-analysis
Yuanchun Li et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2007)
Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors
Jan Oldenburg et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)
Atsushi Yonezawa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Ken A. Olaussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells:: Role of ERCC1 in homologous recombination repair
Michele Cummings et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer
Mihi Yang et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2006)
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values
WJ Loos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cystatin C - A marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy
P. Benoehr et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2006)
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2
G Ciarimboli et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer
J Viguier et al.
CLINICAL CANCER RESEARCH (2005)
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
R Suk et al.
CLINICAL CANCER RESEARCH (2005)
Haploview: analysis and visualization of LD and haplotype maps
JC Barrett et al.
BIOINFORMATICS (2005)
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
W Zhou et al.
CLINICAL CANCER RESEARCH (2004)
Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney
Y Urakami et al.
PHARMACEUTICAL RESEARCH (2004)
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
JS Ryu et al.
LUNG CANCER (2004)
A comparison of Bayesian methods for haplotype reconstruction from population genotype data
M Stephens et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
MK Leabman et al.
PHARMACOGENETICS (2002)
Assessment of cisplatin-induced nephrotoxicity by microarray technology
Q Huang et al.
TOXICOLOGICAL SCIENCES (2001)
DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes
U Vogel et al.
MUTATION RESEARCH-DNA REPAIR (2000)
Share Paper
